Skip to main content
Premium Trial:

Request an Annual Quote

MDS Closes $615M Molecular Devices Acquisition

NEW YORK (GenomeWeb News) — MDS today said it has closed its $615-million acquisition of Molecular Devices.
 
MDS is using the purchase to create a new segment, MDS Analytical Technologies, which is a hybrid of Molecular Devices and the MDS Sciex business.
 
MDS Sciex President Andy Boorn will lead the new business unit.
 
With the deal, Molecular Devices’ stock was delisted yesterday from the Nasdaq Global Select Market. 
 
The two businesses had combined revenues of $432 million last year, and MDS expects Molecular Devices to contribute $190 million in revenue over the coming year, the company said in January.
 
MDS said at the time that its Sciex business will continue its mass spectrometry partnerships with Applied Biosystems and PerkinElmer. 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.